Potential pennant breakout on $MXC over coming days.Initial move of around 100% has had some time to consolidate and soak away remaining supply which has been thinning considerably since the first move. Recently the green bars have been finding much less supply therefore the possibility of a significant move is increasing. If the topside break occurs then 12.0c would be the target
This medical cannabis company have signed several decent sales/distribution agreements recently and have an upcoming catalyst in the form of a definitive multi $M Australian pharmaceutical distributor
Medical
$DCTH Mid Term Goals could put this over $1+ In Weeks - Repost -Reposting as it didn't post properly the first time
$DCTH Highlights for the first quarter of 2017 and the recent weeks include:
First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter.
CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT treatments performed, including eight treatments on a single patient.
Announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC).
The American Journal of Clinical Oncology published a single-center retrospective review finding that the Company’s investigational percutaneous hepatic perfusion (PHP) with Melphalan/HDS offered promising results with a doubling of overall survival (OS), significantly longer progression-free survival (PFS) and hepatic progression-free survival (hPFS) compared with other targeted therapies.
Favorable data from two institutions were presented at the Regional Cancer Therapies Symposium and showed strong tumor response and overall survival with the Company’s investigational PHP therapy in patients with ocular melanoma that metastasized to the liver.
“During the first three months of 2017 we continued to advance our clinical development programs in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, while making steady progress with commercialization of CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath."
“As we announced recently, we have concluded a new SPA agreement with the FDA for the initiation of a pivotal trial for the use of Melphalan/HDS in patients with ICC. This new trial will enroll approximately 295 ICC patients at about 40 clinical sites in the U.S. and Europe, with the primary endpoint of overall survival and with secondary and exploratory endpoints that include safety, progression-free survival, objective response rate and quality-of-life measures. The trial is designed to be cost-effective and conducted in a financially prudent manner, with modest investment in this fiscal year. In conjunction with the FOCUS Trial in ocular melanoma liver metastases, our clinical development programs now include two paths toward potential U.S. market approvals.
“In Europe, we continue to make steady progress with the commercialization of CHEMOSAT. Our first quarter revenue of more than $0.7 million was double the prior year period’s sales, driven primarily by national reimbursement in Germany under the ZE system. With coverage under the ZE system now in place, we expect product sales growth from this market for the remainder of 2017."
"Elsewhere in Europe, we continue to focus on building the clinical and pharmacoeconomic data to support reimbursement applications in other key markets. We expect that positive negotiations for coverage in Germany will support our efforts for payment levels in other markets such as the U.K. and the Netherlands. Securing reimbursement coverage in additional European markets remains critical to future revenue growth for CHEMOSAT,” concluded Dr. Simpson.
As of March 31, 2017, Delcath had cash and cash equivalents of $6.4 million, compared with $4.4 million as of December 31, 2016. During the first quarter of 2017, the Company used $3.8 million of cash to fund operating activities. Delcath believes it has sufficient capital and access to committed capital to fund its operating activities through the end of 2017.
Also check out this article, pretty good read:
insiderfinancial.com
$CTRV 1st Conference Starts Tmrw Continues in the Right DrtnNothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months:
Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Noble Financial reaffirmed a “Buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st.
Teachers Advisors LLC boosted its position by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares worth $1,820,000
Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares worth $3,626,000 after buying an additional 189,634 shares during the last quarter.
Geode Capital Management LLC boosted its position by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares worth $626,000 after buying an additional 7,057 shares during the last quarter.
Morgan Stanley boosted its position in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares worth $493,000 after buying an additional 1,119 shares during the last quarter.
5.49% of the stock is owned by institutional investors.
Very nice averages stakes taken by numerous groups and this is a month or two before the conferences. Shows some agencies might have gotten a sneak peak at the upcoming info. $CTRV
$CTRV Runway Is Cleared for Take-Off$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to move a stock and takes care of his shareholders while at the same time taking care of the company and business. Not to mention 3 drug candidates in clinical trials. Liking what I'm seeing here.
Mazor breakout is not a fakeoutI have been following this Mazor story for over a year, since Medtronic took a stake in them. They are selling their robotic systems well in the US and europe. With Medtronic financial and sales support, as well as their updated systems, this year should be a breakout one. Current target is 60, although longer term I believe it will be much higher (unless they get bought out by Medtronic).
EMC STOCK OUTLOOK FOR APRILGHOST TECHNICAL PREDICTION FOR TSXV:EMC BASED ON ECONOMICAL EVENTS AND KEY BREAKOUT AREAS
Greatness Takes Time.I'm seeing some bashing of this company on a few other outlets.
I think one thing new investors into VDRM need to realize is that greatness takes time. If you bought into it at 0.06-0.07 because somebody told you it was going to run to a $1 overnight, that's all on the trader and not on the stock.
If you look at the chart, this is a very healthy company with a very healthy chart. Slow and steady is the way to go. This company is in store for greatness, and I do believe we see $1 in 2017/2018 however new traders need to realize that a jump from pennies to a dollar happens very rarely unless the company undergoes a R/S or has some suspicious activity going on with it.
If you are newly invested into VDRM and are currently sitting at a loss or near a loss I encourage you to hold tight and be patient. if you sell without the intent to buy back in, I suggest you ignore this ticker for the next year or so.
We will do great things, we have done great things, and great things will continue to happen slowly but surely with this stock.
Millionaires will be made.
Stuck with a bagNot sure whats going on with MJNA that's causing these dramatic dumps.
Could simply be nothing more than pump and dumps intended to allow folks to get cheaper shares before next weeks potential explosiveness. Could also be something more at work behind the scenes within the company that we're not aware of.
Either way I'm weathering the storm. My entry points are 0.04 as well as 0.182, with unfortunately the majority of my shares purchased @ 0.182.
I'm in low spirits today, but I do hope next week will have something great in store for us today.
My estimated closing price for today is around 0.135
Tracking through the end of the weekIm going long on Insy. I've been tracking and accumulating small positions over the last few months(with a purchase at 14.80 & out at 17 most recently. ) and I think this is going to break out of this current zone and enter into a new era leading up to the end of year DEA rescheduling. This will track around 25-30$ until then and we may see it revisit levels from 2015 (around $40-45) once we are reaffirmed with good ER & DEA news. Insys in my humble opinion is a strong buy. Things I would watch out for include manufacturing difficulties as well as supplier deficiencies with their new drug Syndros.
pennies to thousands above cloud and 50 ma medicaldiversify between shorts and longs-strong group see money management in our book on amazon same name -stop loss 50 ma-cci and percent r upper band- weekly above cloud-money flow excellent-adx good-macd crossed
pennies to thousands biotech cancer industrysmall cloud but in
relative strength strong
new hot industry see our book on amazon for selecting stockdsin strong groups
cmf increasing
should pass cloud soon
good volume
long narrow base
pennies to thousands coming out of cloudcoming out of cloud perfect symmetrical triangle
see in our book on amazon the best patterns
good chaikin money flow
excellent relative strength
Canopy Growth Corp. Stock PricesThis shows the stock prices of Canada's largest medical marijuana company.
Canopy Growth Corp. Stock Prices This tracks Canada's largest medical marijuana company's stock prices.
Johnson & Johnson vs USDJohnson & Johnson has seen extreme price consolidation since last November. Since they are a highly diversified healthcare company, currency translations affect their bottom line quite substantially. With the recent contraction of the US Dollar, Johnson & Johnson has broken out of a prolonged trading range. If the dollar continues to contract against other foreign currencies, Johnson & Johnson will make better on their hedges and increase the bottom line substantially, thus increasing free cash flow and overall economic opportunity.
Almost Family Does 38.2% RetracementAlmost Family has done a 38.2% Fibonacci Retracement.
Almost Family has grown EPS by +1340% quarter over quarter, and EPS forecasts for this company are rising fast.
This company has had an EPS surprise for the last 8 quarters!
The company has an excellent P/S of 0.8.
The catalyst for growth is that Americans are living longer and that means more home health care services are needed.
According to a 2014 report by Transparency Market Research, the global home health care market is expected to explode to $303.6 billion in 2020, up from $176.1 billion in 2013, growing at a compound rate of more than 8% per year.
Source: www.guerillastocktrading.com
